GlassScriptPhysician profile
Riaz U Haque
NPI 1881697852
$4,056.31
in general payments reported to CMS, 2019-2025
43 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $802 · 2021: $866 · 2022: $639 · 2023: $286 · 2024: $592 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $583.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $423.86 | 2019-2024 | |
| Novo Nordisk INC | $360.87 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $316.24 | 2020-2025 | |
| Abbott Laboratories | $262.73 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $205.09 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $190.91 | 2019-2020 | |
| Astellas Pharma US INC | $181.67 | 2019-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $153.73 | 2023-2025 | |
| Amgen INC. | $136.78 | 2020-2025 | Repatha, Repatha, Otezla |
| Currax Pharmaceuticals LLC | $102.90 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $79.26 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.51 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $70.13 | 2020-2025 | Trelegy Ellipta, Arexvy |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riaz Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.